Psychedelic-Assisted Therapies Gain Institutional Ground in Europe

Psychedelic-assisted therapies are gaining institutional recognition across Europe, with policy leaders and researchers from 25 countries convening in Brussels to advance clinical frameworks. However, access remains limited and unequal across regions, highlighting disparities in treatment availability. The European Medicines Agency emphasizes the critical need for more robust and standardized clinical evidence to support regulatory approval and therapeutic integration. These developments signal growing scientific legitimacy for psychedelic treatments, particularly for treatment-resistant mental health conditions, while regulatory pathways continue to develop. For patients with conditions like PTSD, depression, and anxiety disorders, institutional progress could eventually expand access to these emerging therapeutic options.